Have a feature idea you'd love to see implemented?
Let us know!
SPRY ARS Pharmaceuticals Inc
Price (delayed)
$15.4
Market cap
$1.49B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$1.46B
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically
Highlights
SPRY's revenue has surged by 128% year-on-year
SPRY's gross profit has surged by 128% year-on-year
ARS Pharmaceuticals's quick ratio has decreased by 46% from the previous quarter but it has increased by 30% YoY
ARS Pharmaceuticals's equity has decreased by 13% YoY and by 3.9% from the previous quarter
Key stats
What are the main financial stats of SPRY
Market
Valuations
Earnings
Shares outstanding
96.94M
Market cap
$1.49B
Enterprise value
$1.46B
Price to book (P/B)
6.93
Price to sales (P/S)
2,982.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,912.87
Revenue
$500,000
EBIT
-$44.84M
EBITDA
-$44.78M
Free cash flow
-$44.23M
Per share
Balance sheet
Liquidity
EPS
-$0.47
Free cash flow per share
-$0.46
Book value per share
$2.22
Revenue per share
$0.01
TBVPS
$2.29
Total assets
$221.97M
Total liabilities
$6.73M
Debt
$160,000
Equity
$215.24M
Working capital
$214.01M
Debt to equity
0
Current ratio
32.82
Quick ratio
32.53
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-8,956%
Gross margin
100%
Net margin
-8,968.4%
Operating margin
-11,347.2%
Return on assets
-19.3%
Return on equity
-19.8%
Return on invested capital
-26.2%
Return on capital employed
-20.8%
Return on sales
-8,968.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRY stock price
How has the ARS Pharmaceuticals stock price performed over time
Intraday
-4.05%
1 week
-4.53%
1 month
12.57%
1 year
342.53%
YTD
181.02%
QTD
6.21%
Financial performance
How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$56.74M
Net income
-$44.84M
Gross margin
100%
Net margin
-8,968.4%
SPRY's revenue has surged by 128% year-on-year
SPRY's gross profit has surged by 128% year-on-year
ARS Pharmaceuticals's net margin has soared by 98% from the previous quarter and by 63% YoY
ARS Pharmaceuticals's operating margin has surged by 98% QoQ and by 60% YoY
Growth
What is ARS Pharmaceuticals's growth rate over time
Valuation
What is ARS Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.93
P/S
2,982.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,912.87
SPRY's EPS is up by 38% year-on-year and by 10% since the previous quarter
The price to book (P/B) is 131% higher than the last 4 quarters average of 3.0
ARS Pharmaceuticals's equity has decreased by 13% YoY and by 3.9% from the previous quarter
SPRY's revenue has surged by 128% year-on-year
The price to sales (P/S) is 91% lower than the last 4 quarters average of 32423.1
Efficiency
How efficient is ARS Pharmaceuticals business performance
SPRY's return on sales has surged by 98% since the previous quarter and by 63% year-on-year
SPRY's return on invested capital is up by 47% year-on-year and by 16% since the previous quarter
The company's return on assets rose by 6% QoQ and by 2% YoY
SPRY's ROE is up by 6% from the previous quarter and by 2.5% YoY
Dividends
What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRY.
Financial health
How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's total liabilities has surged by 81% QoQ but it has decreased by 34% YoY
The company's current ratio fell by 46% QoQ but it rose by 29% YoY
ARS Pharmaceuticals's debt is 100% less than its equity
ARS Pharmaceuticals's debt has plunged by 58% YoY and by 26% from the previous quarter
ARS Pharmaceuticals's equity has decreased by 13% YoY and by 3.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.